Branded Legacy, Inc. Expands Portfolio with Strategic Acquisition in the Intranasal Drug Delivery Market

Branded Legacy, Inc. (OTC: BLEG), a company focused on health and wellness solutions, has announced a significant expansion of its portfolio through the acquisition of Bio-Legacy Evaluative Group. This strategic move, valued at $1.5 million in Preferred D stock, includes all of Bio-Legacy's equity, assets, and intellectual property, marking a pivotal step for Branded Legacy into the rapidly growing intranasal drug delivery market.

The acquisition is particularly significant due to Bio-Legacy's patented naloxone device, which is designed to tackle critical issues related to cost and dosing in a market projected to exceed $1.16 billion by 2032. The device represents a breakthrough in drug delivery technology, offering potential solutions to some of the most pressing health challenges today.

Following the completion of the acquisition, Amin Janmohamed, the current CEO of Bio-Legacy, will assume the roles of CEO and Chairman of Branded Legacy. Under his leadership, the company plans to advance the manufacturing prototyping of the naloxone device by the third quarter of 2025, with the goal of achieving market readiness by the first quarter of 2027.

This acquisition highlights Branded Legacy's dedication to innovation and growth within the biotech and wellness industries. By integrating Bio-Legacy's advanced drug delivery technologies, Branded Legacy is poised to make a substantial impact on the health and wellness sector, addressing critical needs through cutting-edge solutions.